Enliven Therapeutics reports clinical-stage biopharmaceutical developments for a small-molecule oncology pipeline led by ELVN-001, a kinase inhibitor designed to target the BCR::ABL gene fusion in chronic myeloid leukemia. News commonly covers ENABLE clinical-trial updates, CML data presentations, regulatory-development topics, quarterly financial results, and preparation for later-stage development.
Company updates also include leadership and board changes, Nasdaq inducement grants, investor-conference participation, and descriptions of Enliven's precision oncology discovery process built around clinically validated biological targets and differentiated chemistry.
Enliven Therapeutics (ELVN) has reached FDA alignment on the final design of ENABLE-2, its Phase 3 trial of relcobatinib.
The planned randomized trial is expected to enroll approximately 450 adults with chronic myeloid leukemia previously treated with one or more tyrosine kinase inhibitors. Participants will receive relcobatinib or an investigator-selected second-generation inhibitor. The primary endpoint is major molecular response at Week 24, a measure of treatment response; the key secondary endpoint assesses the same response at Week 96. The design makes an improvement of at least 10 percentage points over the control arm sufficient to demonstrate statistical superiority. Enliven remains on track to initiate ENABLE-2 before year-end 2026.
Enliven Therapeutics (ELVN)/b) announced management participation in three September 2026 healthcare investor conferences hosted by Wells Fargo, Baird, and Morgan Stanley.The events take place in Boston on September 8 and in New York on September 15 and 16, featuring fireside chats and 1x1 meetings. A live webcast and 90-day replay of the Morgan Stanley fireside chat will be accessible via the company’s investor relations website.
Enliven Therapeutics (Nasdaq: ELVN) will present data from the ENABLE Phase 1 trial of ELVN-001, a novel selective ATP-competitive BCR::ABL1 inhibitor for previously treated CP-CML, at the SOHO 2026 Annual Meeting in Houston on September 9-12, 2026, in both oral and poster formats.
Enliven Therapeutics (Nasdaq: ELVN) reported second quarter 2026 results and a business update highlighted by positive Phase 1 data for ELVN-001 in chronic myeloid leukemia (CML) and progress toward Phase 3. In the 80 mg once-daily Phase 1b cohort, ELVN-001 achieved a 61% overall major molecular response (MMR) and 48% MMR by 24 weeks, with higher response rates in earlier-line patients and a favorable safety and tolerability profile across 161 treated patients.
According to Enliven, the FDA has aligned on key ENABLE-2 Phase 3 trial design components, 80 mg once-daily was selected as the Phase 3 dose, and ELVN-001 received Fast Track Designation. The company held $895.2 million in cash, cash equivalents and marketable securities as of June 30, 2026, which is expected to fund operations into 2030. Second quarter 2026 R&D expenses were $29.0 million and G&A expenses were $8.2 million, resulting in a net loss of $32.5 million.
Enliven Therapeutics (Nasdaq: ELVN) closed an upsized underwritten public offering of common stock and pre-funded warrants, including full exercise of the underwriters' option.
The company sold 10,533,334 common shares at $37.50 and pre-funded warrants for 1,733,333 shares at $37.499, raising about $460 million in gross proceeds.
Enliven Therapeutics (Nasdaq: ELVN) priced an upsized underwritten public offering of 8,933,334 common shares at $37.50 and pre-funded warrants for up to 1,733,333 shares at $37.499. Gross proceeds are expected to be about $400 million before fees, with closing targeted around June 15, 2026.
Underwriters have a 30-day option to buy up to 1,600,000 additional shares at the public price, less underwriting discounts and commissions.
Enliven Therapeutics (Nasdaq: ELVN) has commenced an underwritten public offering of $250 million in common stock and pre-funded warrants. The company plans to grant underwriters a 30-day option to purchase up to an additional $37.5 million of common shares, subject to market and other conditions.
Enliven Therapeutics (Nasdaq: ELVN) reported updated Phase 1 ENABLE data for ELVN-001 in previously treated CML and alignment with the FDA on key Phase 3 ENABLE-2 design elements.
Among evaluable Phase 1b patients, overall MMR was 54% (61% at 80 mg QD), with 22–30% achieving DMR by 24 weeks. ELVN-001 showed a generally tolerable safety profile in 161 patients, and 80 mg QD was selected as the recommended Phase 3 dose.
Enliven Therapeutics (Nasdaq: ELVN) will host a webcast conference call on June 11, 2026 at 8:30 a.m. ET to discuss updated Phase 1 ENABLE clinical trial data for ELVN-001 in previously treated chronic myeloid leukemia, following an oral presentation at the EHA 2026 Congress.
Enliven Therapeutics (Nasdaq: ELVN) announced participation in two upcoming investor conferences. Management will join fireside chats at the TD Cowen Annual Oncology Innovation Summit on May 27 at 2:30 p.m. ET and the Jefferies Global Healthcare Conference on June 4 at 11:40 a.m. ET.
Live webcasts and 90-day replays will be available via the company's investor relations website.